Literature DB >> 11201991

Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment.

J A Conquer1, M C Tierney, J Zecevic, W J Bettger, R H Fisher.   

Abstract

Fatty acid differences, including docosahexaenoic acid (DHA; 22:6n-3) have been shown in the brains of Alzheimer's patients (AD) as compared with normal age-matched individuals. Furthermore, low serum DHA is a significant risk factor for the development of AD. The relative concentration of DHA and other fatty acids, however, in the plasma of AD patients compared with patients with other kinds of dementias (other dementias; OD), patients who are cognitively impaired but nondemented (CIND), or normal patients is not known. In this study we analyzed the total phospholipid, phosphatidylcholine (PC), phosphatidylethanolamine (PE), and lysophosphatidylcholine (lysoPC) fractions of plasma from patients diagnosed with AD, OD, or CIND and compared them with a group of elderly control subjects with normal cognitive functioning. Plasma phospholipid and PC levels of 20:5n-3, DHA, total n-3 fatty acids, and the n-3/n-6 ratio were lower in the AD, OD, and CIND groups. Plasma phospholipid 24:0 was lower in the AD, OD, and CIND groups as compared with the group of control patients, and total n-6 fatty acid levels were higher in the AD and CIND groups only. In the plasma PE fraction, levels of 20:5n-3, DHA, and the total n-3 fatty acid levels were significantly lower in the AD, OD, and CIND groups. DHA levels were lower in the lysoPC fraction of CIND individuals only. There were no other differences in the fatty acid compositions of the different phospholipid fractions. Therefore, in AD, OD, and CIND individuals, low levels of n-3 fatty acids in the plasma may be a risk factor for cognitive impairment and/or dementia. Interestingly, a decreased level of plasma DHA was not limited to the AD patients but appears to be common in cognitive impairment with aging.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11201991     DOI: 10.1007/s11745-000-0646-3

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  36 in total

Review 1.  Essentiality of fatty acids.

Authors:  A A Spector
Journal:  Lipids       Date:  1999       Impact factor: 1.880

2.  Intakes of dietary docosahexaenoic acid ethyl ester and egg phosphatidylcholine improve maze-learning ability in young and old mice.

Authors:  S Y Lim; H Suzuki
Journal:  J Nutr       Date:  2000-06       Impact factor: 4.798

3.  Regional membrane phospholipid alterations in Alzheimer's disease.

Authors:  M R Prasad; M A Lovell; M Yatin; H Dhillon; W R Markesbery
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

4.  Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients.

Authors:  M Peet; B Murphy; J Shay; D Horrobin
Journal:  Biol Psychiatry       Date:  1998-03-01       Impact factor: 13.382

5.  Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease.

Authors:  B W Brooksbank; M Martinez
Journal:  Mol Chem Neuropathol       Date:  1989-12

6.  Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects.

Authors:  J A Conquer; B J Holub
Journal:  J Nutr       Date:  1996-12       Impact factor: 4.798

7.  Dietary fat intake and the risk of incident dementia in the Rotterdam Study.

Authors:  S Kalmijn; L J Launer; A Ott; J C Witteman; A Hofman; M M Breteler
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

8.  Habitual fish consumption, plasma phospholipid fatty acids, and serum lipids: the Tromsø study.

Authors:  K H Bønaa; K S Bjerve; A Nordøy
Journal:  Am J Clin Nutr       Date:  1992-06       Impact factor: 7.045

9.  Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4.

Authors:  M Mulder; R Ravid; D F Swaab; E R de Kloet; E D Haasdijk; J Julk; J J van der Boom; L M Havekes
Journal:  Alzheimer Dis Assoc Disord       Date:  1998-09       Impact factor: 2.703

10.  Fatty acid composition of serum lipid fractions in relation to gender and quality of dietary fat.

Authors:  T Nikkari; P Luukkainen; P Pietinen; P Puska
Journal:  Ann Med       Date:  1995-08       Impact factor: 4.709

View more
  116 in total

1.  Combination of EPA with Carotenoids and Polyphenol Synergistically Attenuated the Transformation of Microglia to M1 Phenotype Via Inhibition of NF-κB.

Authors:  Nurit Hadad; Rachel Levy
Journal:  Neuromolecular Med       Date:  2017-08-04       Impact factor: 3.843

Review 2.  Diet and Alzheimer's disease: what the evidence shows.

Authors:  Martha Clare Morris
Journal:  MedGenMed       Date:  2004-01-15

3.  Nonpatentable drugs and the cost of our ignorance.

Authors:  Frédéric Calon
Journal:  CMAJ       Date:  2006-02-14       Impact factor: 8.262

4.  Higher serum EPA or DHA, and lower ARA compositions with age independent fatty acid intake in Japanese aged 40 to 79.

Authors:  Rei Otsuka; Yuki Kato; Tomoko Imai; Fujiko Ando; Hiroshi Shimokata
Journal:  Lipids       Date:  2013-02-07       Impact factor: 1.880

5.  GPR40 receptor agonist TAK-875 improves cognitive deficits and reduces β-amyloid production in APPswe/PS1dE9 mice.

Authors:  Chao Liu; Zhao-Yan Cheng; Qing-Peng Xia; Yu-Hui Hu; Chen Wang; Ling He
Journal:  Psychopharmacology (Berl)       Date:  2021-06-26       Impact factor: 4.530

Review 6.  Pathways of polyunsaturated fatty acid utilization: implications for brain function in neuropsychiatric health and disease.

Authors:  Joanne J Liu; Pnina Green; J John Mann; Stanley I Rapoport; M Elizabeth Sublette
Journal:  Brain Res       Date:  2014-12-08       Impact factor: 3.252

7.  Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model.

Authors:  Frédéric Calon; Giselle P Lim; Fusheng Yang; Takashi Morihara; Bruce Teter; Oliver Ubeda; Phillippe Rostaing; Antoine Triller; Norman Salem; Karen H Ashe; Sally A Frautschy; Greg M Cole
Journal:  Neuron       Date:  2004-09-02       Impact factor: 17.173

8.  Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease.

Authors:  Thomas Fraser; Hannah Tayler; Seth Love
Journal:  Neurochem Res       Date:  2009-11-11       Impact factor: 3.996

Review 9.  Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease.

Authors:  Evelin L Schaeffer; Orestes V Forlenza; Wagner F Gattaz
Journal:  Psychopharmacology (Berl)       Date:  2008-10-14       Impact factor: 4.530

Review 10.  Omega-3 fatty acids and cognitive function in women.

Authors:  Jennifer G Robinson; Nkechinyere Ijioma; William Harris
Journal:  Womens Health (Lond)       Date:  2010-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.